Payment overview · 2025
General Payments
$465.59
23 reported records · 7 companies
Healthcare provider profile · identity verified
Phillip Turner, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · IRVINGTON, AL · NPI 1992403315
Verified facts
What the public records show
CMS Open Payments records show Phillip Turner, NP received $465.59 in general payments during 2025 across 23 reported records.
Amgen Inc. accounted for 33.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 191 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $154.46 | 33.2% | 12 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $143.63 | 30.9% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $61.29 | 13.2% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $55.02 | 11.8% | 3 | 2025 |
| MILLICENT US INC | Unresolved — no canonical attribution shown | $19.25 | 4.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.49 | 3.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.45 | 3.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $465.59 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $154.46 | 12 | 2025 |
Source payment records
|
|||||
| Epclusa Normalized: epclusa |
Drug | Gilead Sciences, Inc. | $135.07 | 1 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $61.29 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $35.54 | 11 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $21.63 | 1 | 2025 |
Source payment records
|
|||||
| FEMLYV Normalized: femlyv |
Drug | MILLICENT US INC | $19.25 | 1 | 2025 |
Source payment records
|
|||||
| INTRAROSA Normalized: intrarosa |
Drug | MILLICENT US INC | $19.25 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $18.43 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $16.49 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.45 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.45 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.96 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 191 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
191 | 37 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 496 | 124 |
| Amlodipine Besylate | Amlodipine Besylate | 417 | 102 |
| Lisinopril | Lisinopril | 402 | 95 |
| Metformin Hcl | Metformin Hcl | 256 | 65 |
| Omeprazole | Omeprazole | 195 | 47 |
| Farxiga | Dapagliflozin Propanediol | 191 | 37 |
| Pantoprazole Sodium | Pantoprazole Sodium | 166 | 47 |
| Ibuprofen | Ibuprofen | 164 | 37 |
| Trazodone Hcl | Trazodone Hcl | 164 | 35 |
| Levothyroxine Sodium | Levothyroxine Sodium | 159 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 135 | 37 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 130 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 130 | 33 |
| Meloxicam | Meloxicam | 125 | 29 |
| Carvedilol | Carvedilol | 124 | 30 |
| Losartan Potassium | Losartan Potassium | 97 | 28 |
| Alendronate Sodium | Alendronate Sodium | 93 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 91 | 16 |
| Buspirone Hcl | Buspirone Hcl | 79 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 78 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 74 | 17 |
| Furosemide | Furosemide | 73 | 27 |
| Tizanidine Hcl | Tizanidine Hcl | 67 | 17 |
| Lovastatin | Lovastatin | 65 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 63 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 60 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 59 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 58 | 14 |
| Metoprolol Succinate | Metoprolol Succinate | 53 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 53 | 15 |
| Simvastatin | Simvastatin | 52 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 51 | 45 |
| Sertraline Hcl | Sertraline Hcl | 50 | 11 |
| Glipizide | Glipizide | 47 | 17 |
| Atenolol | Atenolol | 45 | suppressed |
| Eliquis | Apixaban | 43 | 11 |
| Montelukast Sodium | Montelukast Sodium | 42 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 41 | suppressed |
| Januvia | Sitagliptin Phosphate | 41 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 41 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 38 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 38 | 14 |
| Glipizide Er | Glipizide | 37 | suppressed |
| Azithromycin | Azithromycin | 36 | 31 |
| Potassium Chloride | Potassium Chloride | 34 | 12 |
| Linzess | Linaclotide | 33 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 33 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 32 | suppressed |
| Celecoxib | Celecoxib | 31 | suppressed |
| Allopurinol | Allopurinol | 30 | suppressed |
| Famotidine | Famotidine | 30 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 29 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | 12 |
| Jardiance | Empagliflozin | 29 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 28 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 23 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 18 |
| Methylprednisolone | Methylprednisolone | 20 | 18 |
| Nortriptyline Hcl | Nortriptyline Hcl | 20 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 19 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Ezetimibe | Ezetimibe | 18 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Cephalexin | Cephalexin | 17 | 16 |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Mounjaro | Tirzepatide | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 14 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 11 |
| Colchicine | Colchicine | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 11 | 11 |
| Brilinta | Ticagrelor | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $465.59 · 23 records | Amgen Inc. | AIRSUPRA, AREXVY, BREZTRI, Epclusa, FARXIGA, FEMLYV, INTRAROSA, MAVYRET, OTEZLA, REPATHA, SHINGRIX, The Cologuard Plus Collection Kit | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error